Effectiveness and Limitation of Gamma Knife Radiosurgery for Relapsed Central Nervous System Lymphoma: A Retrospective Analysis in One Institution
| Autor: | Masafumi Taniwaki, Yoshiko Fujimoto, Kenichi Nomura, Yosuke Matsumoto, Shigeo Horiike, Manabu Sato, Hiroto Kaneko, Chihiro Shimazaki, Yutaka Kobayashi, Yuriko Kudo-Nakata, Daisuke Shimizu, Satoshi Kimura |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Lymphoma B-Cell medicine.medical_treatment Radiosurgery Disease-Free Survival Recurrence Internal medicine medicine Humans Adverse effect Aged Retrospective Studies Chemotherapy Hematology Brain Neoplasms business.industry Retrospective cohort study Middle Aged medicine.disease Surgery Lymphoma Radiography Radiation therapy Female Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma |
| Zdroj: | International Journal of Hematology. 85:333-337 |
| ISSN: | 0925-5710 |
| Popis: | We describe 6 patients with relapsed central nervous system lymphoma (CNSL) treated with Gamma Knife radiosurgery (GKR). The histologic diagnosis in all 6 patients was diffuse large B-cell lymphoma without human immunodeficiency virus infection. Two patients had intracranial relapse of primary CNSL, and the remaining 4 had CNS relapse of systemic lymphoma. All patients were treated with GKR without severe adverse effects, and all but 1 patient received subsequent chemotherapy shortly after GKR. Four patients showed a complete response, and the remaining 2 patients had a partial response or stable disease. Although the neurologic symptoms disappeared or improved markedly in all patients, all of the diseases recurred or progressed 3 to 13 months after the first GKR. A second GKR was eventually performed in 4 patients. The median overall survival and progression-free survival times after the first GKR were 17 and 11 months, respectively. In our experience, GKR seems to be a useful procedure for the treatment of relapsed CNSL, because it facilitates excellent local control in a short-term treatment period without severe complications, although the efficacy period is not long enough. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink